326. 大理石骨病 Disease details / Clinical trials / Drug dev / DR info

Actimmune
   Indiana University
      2016   Phase 2   NCT02584608   United States
Actimmune registry
   InterMune
      2002   -   NCT00043329   United States
Alemtuzumab
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
AP1903
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 1;Phase 2   EUCTR2016-003226-16-IT   Italy
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
BPX-501 cells
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
BPX-501 T cells
   Bellicum Pharmaceuticals
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
Busulfan
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Calcitriol
   FDA Office of Orphan Products Development
      1999   Phase 3   NCT00004402   -
Campath, busulfan, clofarabine
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2   NCT00638820   United States
Campath-1H
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
CD34+ enriched, T cell depleted donor stem cell product
   Christopher Dvorak
      2010   -   NCT01200017   United States
Cyclophosphamide
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Cyclosporin
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Fludarabine
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Fludarabine monophosphate
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
Hematopoetic stem cell transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States
Horse ANTI-thymocyte globulin
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
IMD preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States
Interferon gamma
   FDA Office of Orphan Products Development
      1999   Phase 3   NCT00004402   -
Interferon gamma-1B
   Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      2016   Phase 2   NCT02666768   United States
Marrow graft transplantation
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
Methotrexate
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Miltenyi biotec clinimacs
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States
Osteopetrosis haploidentical only preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States
Osteopetrosis only preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States
Palliative care
   University of Pittsburgh
      2012   -   NCT03333200   United States
Rabbit ANTI-thymocyte globulin
   Columbia University
      2002   Phase 2/Phase 3   NCT01019876   United States
Rhpth
   University of Chicago
      2003   Phase 1   NCT00145886   United States
Rimiducid
   Bellicum Pharmaceuticals
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rivogenlecleucel
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom
Rivogenleucleucel
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom
Stem cell or umbilical cord blood transplantation
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2   NCT00638820   United States
Stem cell transplantation
   Masonic Cancer Center, University of Minnesota
      2014   Phase 2   NCT02171104   United States
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Systemic chemotherapy and antibodies
   St. Jude Children's Research Hospital
      2004   -   NCT00145587   United States
Thymoglobulin
   Tehran University of Medical Sciences
      2009   Phase 2/Phase 3   NCT01087398   Iran, Islamic Republic of
Total lymphoid irradiation
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States
      2007   Phase 2   NCT00638820   United States
Umbilical cord blood transplantation
   Masonic Cancer Center, University of Minnesota
      2008   Phase 2/Phase 3   NCT00775931   United States